Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 3/20 | 0.50 |
| ▸ | GNPAT | O15228 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 5/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.40 |
| ▸ | MMP1 | P03956 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30798028 | 0.85 | GNPAT (0.53) | GNPATENPEPMMENOD1 | |
| SCHEMBL30656951 | 0.85 | BMP1 (0.50) | BMP1GNPATDPP4MMP2ENPEP | |
| SCHEMBL30798044 | 0.85 | GNPAT (0.53) | GNPATENPEPMMENOD1 | |
| SCHEMBL30355295 | 0.85 | MME (0.49) | GNPATENPEPMMENOD1 | |
| SCHEMBL29378709 | 0.85 | MME (0.49) | GNPATENPEPMMENOD1 | |
| SCHEMBL8650914 | 0.85 | MME (0.49) | GNPATENPEPMMENOD1 | |
| SCHEMBL7825934 | 0.85 | MME (0.49) | GNPATENPEPMMENOD1 | |
| SCHEMBL8648570 | 0.85 | MME (0.49) | GNPATENPEPMMENOD1 | |
| Hydrochloric Acid SCHEMBL10547776 | 0.84 | BMP1 (0.57) | BMP1DPP4MMP2MMP9MMP8 | |
| SCHEMBL21664134 | 0.84 | BMP1 (0.49) | BMP1GNPATDPP4MMP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | BMP1 621/4885GNPAT 3112/4885DPP4 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.